Posters
CKM: Clinical - Epidemiology and Outcomes
October 24, 2026 | 10:00 AM - 12:00 PM
Location: Exhibit Hall A, Convention Center
Session Description
Poster Session
Posters
Sex-Specific Trends in Mortality Among Patients with CKD and Peripheral Vascular Disease in the United States, 1999-2024: A Joinpoint Analysis
Inside CKD-HTN: The Effect of Hypertension Control Across KDIGO Risk Categories on CKD Burden
Associations of Environmental Per- and Polyfluoroalkyl Substances-Metal Mixtures with Blood Pressure and Cardiovascular Risk Among US Veterans and Civilians
Association of Cardiovascular-Kidney-Metabolic Burden with CKD in a National US Cohort
Age-Stratified Analysis of CKD and Diabetes Trends: Questioning the Adequacy of Uniform Diagnostic Criteria
Joint Association of Triglyceride-Glucose Index and Systemic Inflammation Index with Mortality in Cardiovascular-Kidney-Metabolic Syndrome Stages 0-3: NHANES, 1999-2018
Geographic Clustering of Cardiovascular-Kidney-Metabolic (CKM) Syndrome in the United States
PREVENT Risk Scores as Predictors of Kidney Outcomes
Comparative Risk of Major Adverse Cardiovascular Events in Patients with CKD Receiving Triglyceride-Targeting Lipid-Lowering Therapies vs. Statins
Cardiovascular and Renal Outcomes of Niacin in Patients with CKD: A Causal Mediation Analysis
Association Between Plasma Calciprotein Particle Levels and Longitudinal Changes in the Renal Resistive Index in Community-Dwelling Adults
AHA PREVENT Equations and Coronary Artery Calcium for Atherosclerotic Cardiovascular Disease Risk Prediction in CKD
2022 American Heart Association/American College of Cardiology Heart Failure Stages and Incident Heart Failure Risk in CKD
Serum Magnesium and Metabolic Phenotypes in CKD: Insights from the CRIC Study
Association of Cardiac Structure, Function, and Injury with Change in Physical Performance in Patients with CKD
Severe Kidney Events, CKD Hospitalizations, and Health Care Costs in Patients with CKD and Heart Failure in the Multinational CaRe Study
Association of Finerenone Use with Real-World Clinical Outcomes in Patients with CKD and Type 2 Diabetes (T2D)
Characteristics of Patients with Comorbid CKD and Hypertension in the United States and Finland
Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular-Kidney-Metabolic Syndrome Increase the Risk of Major Cardiovascular Events
Lowering Mortality of Cardiovascular-Kidney-Metabolic Syndrome (CKM) by a Nonpharmacological Approach: Leveraging Resting Heart Rate to Maximize the Effect of Physical Activity
Claims-Based Modeling Identifies High-Risk Cardiovascular-Kidney-Metabolic Profiles in CKD Without Laboratory Data
Cardiovascular-Kidney-Metabolic Syndrome Stages and the Full Spectrum of Cause-Specific Mortality: A Nationwide Korean Cohort Study
Kidney and Cardiovascular Outcomes of SGLT2 Inhibitors as Add-On Therapy to Metformin in Frail Patients with Type 2 Diabetes
Bridging the Treatment Gap: SGLT2 Inhibitors and GLP-1 Receptor Agonists and Outcomes in Patients with Diabetes and CKD
Cardiorenal Complexity of Anemia: Data from CARDIOREN
Associations of Life's Simple 7 with Kidney Tubular and Glomerular Measures in Cross-Section and over 10 Years in Community-Living Individuals
Circulating Endotrophin Is Associated with Incident Kidney Disease, with Differential Effects Across Obesity Phenotypes in the General Population
Finerenone Safety and Effectiveness Across CKD Stages in Type 2 Diabetes: Analysis of Four US Databases from the FOUNTAIN Platform
Cardiorenal Outcomes and GLP-1 Receptor Agonist Therapy in Diabetic Kidney Disease: A Race- and Ethnicity-Stratified Real-World Cohort Study
GLP-1 Receptor Agonists (RAs) Use and Kidney and Cardiovascular Outcomes in Adults with CKD and Obesity Without Diabetes: A Retrospective Real-World Study
GLP-1 Receptor Agonists vs. Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors in Patients with Diabetes, ESKD, and Heart Failure on Dialysis: A Target Trial Emulation
Comparative Effectiveness of GLP-1 Receptor Agonists vs. Mineralocorticoid Receptor Antagonists as Fourth-line Therapy in Patients with Resistant Hypertension and Overweight or Obesity
Sounds of Silence: Major Adverse Cardiovascular Events Uncovers Highest Risk in Native Hawaiian and Pacific Islander Patients with Kidney-Metabolic Dysfunction in Hawai'i
Continuous Glucose Monitoring and Risk of Progression to ESKD in a National CKD Cohort
Albuminuria and Progression to ESKD in Adults with Diabetes: A Retrospective Cohort Study of Sex, Ethnic, and Age Disparities
Steroidal Mineralocorticoid Receptor Antagonists and Kidney Outcomes in Hypertensive Patients with CKD: A Large Real-World Study
Comparing EMPA-KIDNEY Trial Participants with Trial-Eligible, Real-World Patients
Ambulatory Blood Pressure Phenotypes Among HIV-Positive and -Negative Adults with CKD in Rural Uganda and Kenya: The SEARCH CKD Study
Kidney Markers Predict Mortality in Wild-Type Transthyretin Cardiac Amyloidosis: Implications for Earlier Screening
Association Between eGFR and Albuminuria (GA) Staging and Comorbidity Risk in Patients with Diabetic Kidney Disease: A Retrospective Cross-Sectional Study
Prescription Trends and Kidney Outcomes Associated with SGLT2 Inhibitor Use in Patients with Type 2 Diabetes and CKD
Advanced Cardiovascular-Kidney-Metabolic Syndrome Stage and Early eGFR Recovery After Kidney Transplantation
Safety and Efficacy of GLP-1 Receptor Agonists Across the Full Spectrum of CKD: A Real-World Cohort Study
Tirzepatide in Mexican Patients with CKD: An Observational Study
Real-World Mortality and Hospitalization Outcomes Associated with GLP-1 Receptor Agonist Use in Patients on Dialysis
Vitamin D Deficiency as an Independent Predictor of Coronary Artery Calcification Severity in Cardiovascular-Kidney-Metabolic Syndrome: A Dual-Center Observational Study
Lipid Imbalance and Progression of Coronary Artery Calcification in CKD: A Differential Effect Across CKD Stages and Dialysis Modalities
Remnant Cholesterol Inflammatory Index and C-Reactive Protein-Triglyceride-Glucose Index Surpass CRP in Identifying CKD Severity Among Patients with Cardiovascular-Kidney-Metabolic Syndrome
Random Plasma GLP-1 and Diabetic Kidney Disease in Adults with Type 2 Diabetes: A Multicenter Iraqi Case-Control Study
Effect of Incretin Receptor Agonists with or Without SGLT2 Inhibitors on Cardiorenal Metabolic Outcomes in Patients with CKD and Obesity
Systemic Inflammation Mediates the Association of Kidney Function with Heart Rate Variability in CKD: The CRIC Study
Cardiovascular-Kidney-Metabolic Effects of Subcutaneous Semaglutide in Patients with Type 2 Diabetes in a Latin Population: A One-Year Prospective Observational Study
Temporal Trajectory of N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) and Carbohydrate Antigen (CA-125) Before Dialysis Initiation: Insights into Cardiorenal Interactions in Advanced CKD
Urinary Metabolomic Signatures Predict Rapid eGFR Decline in the Cardiovascular-Kidney-Metabolic (CKM) Syndrome Population
Kidney Outcomes with Empagliflozin 10 mg vs. 25 mg: Subgroup Analyses in Patients with Diabetes, Heart Failure, and CKD
Ticagrelor vs. Clopidogrel Treatment in Chinese Patients with CKD After Percutaneous Coronary Intervention: Implications for East Asia
SGLT2 Inhibitors in Older Patients: Early Cardiorenal, Functional, and Biological Changes in Clinical Practice
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors Significantly Reduce Hypercholesterolemia in Patients on Dialysis
Prognostic Value of the Stress Hyperglycemia Ratio for Cardiovascular Events in Patients with Moderate-to-Severe CKD and Heart Failure